RH Bophelo Rwanda Listing Sens Announcement

Loading player...
Secondary Listing Of RH Bophelo On The Rwanda Stock Exchange. RH Bophelo will list on the RSE by way of an introduction on Monday, 1 June 2020 at the opening of the market.
RH Bophelo listed on the Johannesburg Stock Exchange (“JSE”) as a special purpose acquisition company (“SPAC”) in July 2017 with R500 million in new capital being raised (“JSE Listing”). TheJSE Listing allowed RH Bophelo to access the initial capital required to start operating and opened the door for the general public to acquire shares in a fully black-owned and entirely African healthcare company that offers growth and returns in a defensive asset class. RH Bophelo has since been converted into an Investment Entity as defined in terms of Section 15 of the JSE Listings Requirements.
In April 2020, the Directors, subject to approval by the relevant regulatory authorities, approved RH Bophelo’s proposed secondary listing on the Rwanda Stock Exchange (“RSE”) (“RSE Listing”). RH Bophelo’s primary listing and exchange will remain as the JSE with the RSE Listing being a secondary listing (“Secondary Listing”).
26 May 2020 12PM English South Africa Business News · Investing

Other recent episodes

BofA Slashes SA Growth Forecast as Inflation Surges

Bank of America has cut South Africa’s 2026 GDP growth forecast to 1.3%, warning that higher oil and fertilizer prices will keep inflation above 4% for most of the year. Economist Tatonga Rusike explains
23 Apr 3PM 11 min

Understanding SA’s First Wealth Score

Franc unveils South Africa’s first-ever Wealth Score, revealing that financial habits—not income—are the strongest predictor of financial health. We unpack why SA’s national score is 45/100 and the behavior gap between knowing and doing with Dr. Thomas Brennan, founder and CEO of Franc.
23 Apr 3PM 13 min

Clicks Lifts HEPS 8% Despite Warehouse Disruptions.

Clicks delivered firm interim results with diluted HEPS up 8.1%, even as warehouse system delays cost an estimated R175 million in lost sales. CEO Bertina Engelbrecht discusses pharmacy growth, trading margins, and festive‑season competition.
23 Apr 2PM 16 min